Key facts, as of
As of October 8, 2026, Boston Scientific (BSX) trades at $41.58, down 56.6% over the past year. Its 52-week range runs from $41.50 to $105.65; the price is 60.6% below that high. It is 62.0% below its all-time high of $109.50, reached in September 2025, and at the lowest price it has traded at since November 2022. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +83.4%, against +312.9% for the S&P 500 (SPY). It sits 31.8% below its 200-day average of $60.95, the usual sign of a long-term downtrend. Its 30-day volatility is 27.6% annualized, which we rate medium risk. It has a trailing P/E of 16.8.
Cite: Portfolio Terminal, "Boston Scientific (BSX) stock analysis", 2026-10-08. https://portfolio-terminal.com/analyse/bsx
Where it trades today
trading 0% of the way up its 52-week range
How the price has moved
How far it is from its record
Boston Scientific (BSX) is 62.0% below its all-time high of $109.50, reached in September 2025, and at the lowest price it has traded at since November 2022. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +83.4%, against +312.9% for the S&P 500 (SPY).
What to weigh before acting
What Matters Now
- The read on the stock is often driven by pipeline durability, reimbursement pressure, and whether new launches can offset patent cliffs.
- BSX trades at 16.8x earnings versus 22.0x for the sector, which means the rerating case depends on proving the discount is too harsh.
- Recent realized volatility is running around 27.6%, above the sector norm of 22.0%, so position sizing matters more than usual.
- BSX remains in a bearish short-term trend and sits 60.6% below its high, which raises the bar for any thesis that depends on fast multiple expansion.
Portfolio Use Case
- BSX is more useful for investors comparing conviction names inside healthcare than for someone looking for a passive “set and forget” holding.
- The beta profile suggests it can fit a quality or lower-volatility sleeve more naturally than a high-octane tactical basket.
- The stock becomes more useful when paired with an explicit catalyst watchlist, because sector sentiment can shift quickly around policy, rates, or pipeline news.
What Would Change the View
- A recovery in price alone would not be enough to improve the view; the thesis needs confirmation from improving business or valuation signals.
- Volatility is already above the sector norm, so even a correct long-term thesis can be painful if the position size is too aggressive.
- There is little income cushion here, so total return depends mainly on price appreciation and execution staying on track.
Methodology
- Price, market cap, beta, yield, and liquidity fields for BSX come from Yahoo Finance quote and summary data.
- 30-day volatility is calculated from recent daily returns and annualized using a 252-trading-day convention.
- Sector context uses stored benchmark averages for Healthcare so each page compares the ticker against a stable peer baseline rather than against the whole market.
- Peer comparisons use the Portfolio Terminal coverage set and highlight nearby listed alternatives such as UNH, JNJ, PFE.
Sources
- Yahoo Finance quote dataopen →
Live quote, valuation, beta, yield, and volume fields used for BSX. Last refresh: Oct 8, 2026, 10:10 AM.
- Portfolio Terminal methodologyopen →
Explains how analytics, refresh cadence, and portfolio interpretation work across the product.
- Peer set and coverage context
Comparative context for this page is anchored around nearby tracked names such as UNH, JNJ, PFE.
What Boston Scientific does
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological…
Employees
59,000
Industry
Medical Devices
Headquarters
Marlborough, United States
What analysts expect
BSX carries a buy consensus from 29 analysts, with an average price target of $59.90 versus $41.58 today (+44.1%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
BSX generated $21.00B in trailing revenue (7.5% year over year), with a 17.5% net margin, and $2.45B of free cash flow, against $12.09B of net debt.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $20.07B | $13.85B | $3.97B | $2.90B | $1.96 | $3.40B |
| 2024 | $16.75B | $11.49B | $3.00B | $1.85B | $1.26 | $2.37B |
| 2023 | $14.24B | $9.89B | $2.42B | $1.59B | $1.08 | $1.70B |
| 2022 | $12.68B | $8.73B | $2.03B | $698.00M | $0.45 | $914.00M |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
Which ETFs hold it
BSX is in 7 of the 30 ETFs we track. It weighs most in XLV: 1.05% of the fund, holding #23 of 62.
Famous investors who hold it
BSX is in the latest 13F of 1 of the 15 famous investors we follow. Renaissance Technologies (Founded by Jim Simons) holds the most of it: 0.14% of the portfolio, position #152 of 2,931, as of Q2 2026.
How it sits in healthcare
Defensive sector including pharmaceuticals, biotech, medical devices, and healthcare services.
The companies it competes with
BSX beside the healthcare names it is usually measured against.
What the chart is saying
In a downtrend, below both moving averages.
downtrend- Price is 10.9% below its 50-day average and 31.8% below its 200-day.
- RSI at 32 is neither stretched nor washed out.
- The nearest ceiling is $42.49 (+2.2%).
A description of the chart, not advice. Indicators describe what the price has done; none of them knows what it does next.
Questions people ask about it
Is BSX a good investment in 2026?
Boston Scientific trades at a P/E ratio of 16.8, with medium volatility (27.6% annualized). Recent trend shows weakness.
What is the risk level of BSX?
Based on 30-day volatility of 27.6%, BSX has MEDIUM risk. Beta of 0.57 indicates lower sensitivity to market movements than average.
Does BSX pay dividends?
Boston Scientific currently does not pay a regular dividend.
How far is BSX from its all-time high?
Boston Scientific is 62.0% below its all-time high of $109.50, reached in September 2025, and at the lowest price it has traded at since November 2022. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +83.4%, against +312.9% for the S&P 500 (SPY).
Which ETFs hold BSX?
7 of the 30 popular ETFs we track hold Boston Scientific. The largest weights: XLV (1.05%), VTV (0.13%), VUG (0.11%), VOO (0.11%) and IVV (0.10%). Measured on each issuer's full holdings file, dated August 31 to September 24, 2026.
How much of VOO is BSX?
0.11%, as of August 31, 2026: BSX is holding #170 of 505 in Vanguard's file for VOO. $1,000 in VOO puts about $1.08 in Boston Scientific.
Which famous investors own BSX?
Renaissance Technologies (0.14% of Founded by Jim Simons's 13F), according to their latest Form 13F filings with the SEC (Q2 2026). A 13F lists US long positions 45 days after the quarter ends, so it can be out of date.
What is the analyst price target for BSX?
The average analyst price target for Boston Scientific (BSX) is $59.90 based on 29 analyst estimates, about 44.1% above the current price of $41.58. The published range runs from $44.00 to $94.00.
How much revenue does BSX generate?
Boston Scientific reported $21.00B in trailing twelve-month revenue. Revenue growth is running at 7.5% year over year. Net margin sits at 17.5%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.
Compare BSX with anything
Five years side by side: what $10,000 became, how far each fell, whether they move together.